Tactile Systems Technology, Inc. (NASDAQ:TCMD ) Q1 2025 Earnings Conference Call May 5, 2025 5:00 PM ET Company Participants Sam Bentzinger - Investor Relations, Gilmartin Group LLC Sheri Dodd - Chief Executive Officer Elaine Birkemeyer - Chief Financial Officer Conference Call Participants Margaret Kaczor Andrew - William Blair Ryan Zimmerman - BTIG Anderson Schock - B. Riley Securities Operator Welcome, ladies and gentlemen, to the First Quarter 2025 Earnings Conference Call for Tactile Medical.
Tactile Systems Technology (TCMD) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.05 per share a year ago.
Tactile Systems Technology, Inc. (NASDAQ:TCMD ) Q4 2024 Earnings Conference Call February 18, 2025 5:00 PM ET Company Participants Sam Bentzinger - Investor Relations, Gilmartin Group LLC Sheri Dodd - Chief Executive Officer Elaine Birkemeyer - Chief Financial Officer Conference Call Participants Max Smock - William Blair Adam Maeder - Piper Sandler Iseult McMahon - BTIG Kyle Bauser - B. Riley Securities Suraj Kalia - Oppenheimer & Company Operator Please standby.
4 Aug 2025 (In 2 weeks) Date | | 0.17 Cons. EPS | - EPS |
5 May 2025 Date | | - Cons. EPS | - EPS |
18 Feb 2025 Date | | - Cons. EPS | 0.4 EPS |
4 Nov 2024 Date | | 0.18 Cons. EPS | 0.21 EPS |
5 Aug 2024 Date | | 0.12 Cons. EPS | 0.18 EPS |
4 Aug 2025 (In 2 weeks) Date | | 0.17 Cons. EPS | - EPS |
5 May 2025 Date | | - Cons. EPS | - EPS |
18 Feb 2025 Date | | - Cons. EPS | 0.4 EPS |
4 Nov 2024 Date | | 0.18 Cons. EPS | 0.21 EPS |
5 Aug 2024 Date | | 0.12 Cons. EPS | 0.18 EPS |
Medical - Devices Industry | Healthcare Sector | Sheri Louise Dodd CEO | XSTU Exchange | US87357P1003 ISIN |
US Country | 1,037 Employees | - Last Dividend | - Last Split | 28 Jul 2016 IPO Date |
Tactile Systems Technology, Inc. is a pioneering medical technology entity focused on designing, developing, and marketing innovative medical devices tailored to treat chronic diseases that are often neglected by the current healthcare model, predominantly in the United States. Founded in 1995 and strategically headquartered in Minneapolis, Minnesota, the company has carved a niche for itself by offering cutting-edge solutions that aim to improve the quality of life for patients suffering from conditions such as lymphedema, chronic venous insufficiency, and respiratory diseases. Through its commitment to advancing medical care at home, Tactile Systems Technology stands at the forefront of facilitating accessible and effective treatment options beyond the confines of traditional hospital settings.
A revolutionary pneumatic compression device, the Flexitouch Plus is designed to provide comprehensive treatment for lymphedema within the comfort of the patient's home. This system utilizes advanced technology to simulate manual lymphatic drainage therapy, which helps reduce swelling and manage symptoms effectively, providing relief to those suffering from this often debilitating condition.
Understanding the challenges faced by individuals with venous disorders, Tactile Systems Technology introduced the Entre Plus System, a portable pneumatic compression device that caters to the at-home treatment of conditions such as lymphedema and chronic venous insufficiency, including the painful and hard-to-heal venous leg ulcers. This device offers a practical solution for patients to manage their conditions effectively from the comfort of their homes, enhancing their quality of life.
With the digital age revolutionizing healthcare management, Tactile Systems Technology developed Kylee, a user-friendly mobile application aimed at empowering patients to better understand lymphedema, monitor their symptoms and treatment progress, and seamlessly share this data with their healthcare providers. This innovative app fosters patient engagement and encourages active participation in their healthcare journey, promoting better outcomes.
The AffloVest represents a significant advancement in respiratory care, offering a portable high frequency chest wall oscillation vest designed to aid patients struggling with retained pulmonary secretions due to conditions like bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Its portability ensures patients can receive consistent treatment, regardless of their location, making it a vital tool in managing respiratory conditions more effectively.